Data Analysis of THINQURE 20 in COVID 19 Patients
Completed
- Conditions
- Coronavirus as the cause of diseases classified elsewhere,
- Registration Number
- CTRI/2021/03/032471
- Lead Sponsor
- Thinq Pharma CRO Limited
- Brief Summary
A Non-Interventional, Retrospective, Observational study to analyze safety, efficacy and tolerability of THINQURE 20 in COVID-19 patients.
Base on data available we want to analyze THINQURE 20 in COVID-19 patients.
Based on data analysis we will go for a pivotal study
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
- We will consider the following criteria for retrospective analysis.
- Male or Female subjects of age 18 to 75 years (both inclusive).
- Subjects diagnosed with COVID-19 by RT-PCR.
- Patients provided oral & nasal swabs for test 4.
- Females of child-bearing potential (i.e., who were not chemically or surgically sterilized or who were not post-menopause) must have had a negative urine pregnancy test.
- Females of child-bearing potential who have used a medically accepted method of contraception that was considered reliable in the judgment of the investigator.
- Subjects who have taken Thinqure 20 as prescribed by Investigator.
Exclusion Criteria
- Subjects were excluded on the following basis: 1.
- Patients with a history of intracranial bleeding 2.
- Patients without a completed medical history 3.
- Patients, who were suffering from any haemoglobinopathies such as thalassemia that could interfere with oxygen carriage in the blood.
- Patients, who were smokers or consumed alcohol.
- Patients, who were suffering from active malignancy along with squamous cell or basal cell skin cancer.
- Females who were not ready to use acceptable contraceptive methods during the course of study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in viral load from baseline to end of study visit. Day 1 to Day 5
- Secondary Outcome Measures
Name Time Method The assessment of safety and tolerability of Investigational Product. Day 1 to Day 5
Trial Locations
- Locations (1)
YCM Hospital Pune
🇮🇳Pune, MAHARASHTRA, India
YCM Hospital Pune🇮🇳Pune, MAHARASHTRA, IndiaDr Pravin SoniPrincipal investigator9822057511pravinsoni028@gmail.com